Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Shared Research Inc.
$0.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

MEDINET Co Ltd announces trial results in pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma


Wednesday, 20 Aug 2014 02:00am EDT 

MEDINET Co Ltd:Announced trial results in pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma, with The University Of Tokyo Hospital.One of eight participators was reputed as Complete Response, one as Partial Response and three as Stable Disease. 

Company Quote

239.0
-8.0 -3.24%
22 Dec 2014